Ocumension Therapeutics (HKG:1477) expects revenue to come between 408 million yuan and 420 million yuan for the year ended Dec. 31, up to 70.5% higher compared with the 246.4 million yuan in the previous year, according to a Wednesday filing with the Hong Kong bourse.
The company attributed the increase in revenue to an increase in sales of its corr lle products' among other factors.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.